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Abstract
Telomeres are considered as universal anti-cancer targets, as
telomere maintenance is essential to sustain indefinite cancer
growth. Mutations in telomerase, the enzyme that maintains
telomeres, are among the most frequently found in cancer. In addi-
tion, mutations in components of the telomere protective complex,
or shelterin, are also found in familial and sporadic cancers. Most
efforts to target telomeres have focused in telomerase inhibition;
however, recent studies suggest that direct targeting of the shel-
terin complex could represent a more effective strategy. In particu-
lar, we recently showed that genetic deletion of the TRF1 essential
shelterin protein impairs tumor growth in aggressive lung cancer
and glioblastoma (GBM) mouse models by direct induction of
telomere damage independently of telomere length. Here, we
screen for TRF1 inhibitory drugs using a collection of FDA-approved
drugs and drugs in clinical trials, which cover the majority of path-
ways included in the Reactome database. Among other targets, we
find that inhibition of several kinases of the Ras pathway, includ-
ing ERK and MEK, recapitulates the effects of Trf1 genetic deletion,
including induction of telomeric DNA damage, telomere fragility,
and inhibition of cancer stemness. We further show that both
bRAF and ERK2 kinases phosphorylate TRF1 in vitro and that these
modifications are essential for TRF1 location to telomeres in vivo.
Finally, we use these new TRF1 regulatory pathways as the basis
to discover novel drug combinations based on TRF1 inhibition, with
the goal of effectively blocking potential resistance to individual
drugs in patient-derived glioblastoma xenograft models.
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Introduction
Telomeres are heterochromatic structures at the ends of chromo-
somes, which are essential for chromosome stability (Blackburn,
1991). They are composed by tandem repeats of the TTAGGG repeti-
tive sequence bound by the so-called shelterin complex, which is
formed by six proteins named TRF1, TRF2, RAP1, TPP1, TIN2, and
POT1. The shelterin complex constitutes the so-called capping of the
telomeres, which is essential for their protection, preventing telom-
eres from fusion to other chromosome ends, from telomere fragility,
and from degradation (De Lange, 2005). Also, the shelterin complex
prevents the recognition of telomeres as double-strand DNA breaks
(DSB) and the subsequent activation of a persistent DNA damage
response (DDR; De Lange, 2005). Telomeres get shorter with aging
as cells divide to regenerate tissues, and when they reach a very
short length, they can contribute to physiological aging (Hemann &
Greider, 2000; Samper et al, 2001). Telomere shortening can be
compensated through de novo addition of telomeric repeats by
telomerase, a reverse transcriptase composed by a catalytic subunit
(TERT) and an RNA component (Terc; Greider & Blackburn, 1985).
Telomeres can also be elongated by an alternative mechanism
known as alternative lengthening of telomeres (ALT), which is
based in homologous recombination between chromosome ends
(Bryan et al, 1997).
The majority of cancer cells aberrantly activate telomerase or
ALT mechanisms to be able to divide indefinitely (Kim et al, 1994;
Bryan et al, 1995; Shay & Bacchetti, 1997; Barthel et al, 2017). More
than 90% of human tumors aberrantly overexpress telomerase (Kim
et al, 1994; Shay & Bacchetti, 1997; Joseph et al, 2010), while the
remaining telomerase-negative tumors activate ALT (Bryan et al,
1997; Barthel et al, 2017). For this reason, telomeres have been
considered as potential anti-cancer targets.
Most studies have focused in telomerase inhibition as therapeutic
approach for telomere targeting in cancer. One of the most advanced
anti-telomerase therapies is GRN163L, also called Imetelstat (Harley,
2008; Joseph et al, 2010). However, clinical trials for several cancer
types had shown that this strategy has some limitations (Parkhurst
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et al, 2004; Middleton et al, 2014; El Fassi, 2015). In mouse models
of cancer, the anti-tumorigenic effect of telomerase inhibition is only
achieved when telomeres reach a critically short length, and this
effect is lost in the absence of the p53 tumor suppressor gene, which
is frequently mutated in cancer (Gonzalez-Suarez et al, 2000; Perera
et al, 2008). Also, cancer cells could activate ALT to overcome
telomerase inhibition. Thus, alternative therapies of telomere target-
ing should be developed in order to efficiently target telomeres in
cancer.
In this regard, our group and others have found that not only
telomerase but also shelterin proteins are often mutated in cancer.
In particular, POT1 is mutated in several types of sporadic and
familial human tumors, including chronic lymphocytic leukemia
(CLL; Ramsay et al, 2013), familial melanoma (Robles-Espinoza
et al, 2014; Shi et al, 2014), Li–Fraumeni-like families (LFL) with
cardiac angiosarcomas (CAS; Calvete et al, 2015), glioma (Bain-
bridge et al, 2015), mantle cell lymphoma (Zhang et al, 2014), and
parathyroid adenoma (Newey et al, 2012). Also, previous studies
from our group suggested that targeting the shelterin complex
through inhibition of one of its central components, TRF1, leads to a
rapid telomere dysfunction independently of telomere length, thus
avoiding the shortcomings of telomerase inhibition (Garcia-Beccaria
et al, 2015; Bejarano et al, 2017). In particular, we reported that
induction of telomere uncapping by either Trf1 genetic depletion or
TRF1 chemical inhibition can effectively block initiation and
progression of aggressive tumors in both lung cancer and glioblas-
toma mouse models, in a manner that is independent of telomere
length (Garcia-Beccaria et al, 2015; Bejarano et al, 2017). We
further demonstrated that TRF1 abrogation in normal tissues was
tolerated and did not result in decreased mouse survival or severe
defects in tissues (i.e., TRF1 abrogation did not affect brain olfactory
or memory functions nor affected highly proliferative tissues) (Gar-
cia-Beccaria et al, 2015; Bejarano et al, 2017). These findings were
recapitulated by using TRF1 chemical inhibitors. In particular, we
found that TRF1 is phosphorylated at different residues by AKT and
that these modifications regulate TRF1 foci formation in vivo (Men-
dez-Pertuz et al, 2017). Thus, PI3K inhibitors, as well as inhibitors
of the PI3K downstream target AKT, significantly reduced TRF1
telomeric foci and lead to increased telomeric DNA damage and
fragility, also impairing the growth of lung and GBM cells (Garcia-
Beccaria et al, 2015; Bejarano et al, 2017).
Given these results, here we set to discover additional TRF1
modulatory pathways by carrying out a screening with FDA-
approved drugs or drugs that are currently in clinical trials, and
which cover the majority of known cancer pathways. We found
several drugs that inhibit TRF1 independently of the Pi3K pathway,
including inhibitors of some of the most deregulated pathways in
cancer. Among these pathways, here we demonstrate an unprece-
dented role of the Ras pathway in regulating telomere protection.
Finally, we used these new TRF1 regulatory pathways as a rational
to discover novel drug combinations based on TRF1 inhibition,
which effectively block resistance to individual drugs in patient-
derived glioblastoma mouse models. The results shown here
uncover the importance of telomere capping for cancer cells and
identify novel therapeutic strategies based on telomere targeting.
Results
Identification of novel TRF1 regulatory pathways
To identify novel pathways that regulate TRF1 protein levels, we
used a cell-based high-throughput screening to determine TRF1 foci
fluorescence upon treatment with different drugs (Garcia-Beccaria
et al, 2015). We screened a CNIO collection of 114 anti-tumoral
drugs, which are either approved by the Food and Drug Administra-
tion (FDA) or in clinical trials, and which cover 20 of the 26 path-
ways included in Reactome database (Fig EV1A). To this end, we
treated CHA-9.3 mouse lung cancer cells (Garcia-Beccaria et al,
2015) with the compounds at 1 lM concentration during 24 h,
followed by immunofluorescence analysis using anti-TRF1 antibody
to quantify TRF1 foci fluorescence (Fig 1A). As positive controls,
we used PI3K inhibitors (PI3Ki), previously shown by us to inhibit
TRF1 telomeric foci (Mendez-Pertuz et al, 2017).
We found several drugs with the ability to downregulate TRF1
levels, including inhibitors of some of the most deregulated path-
ways in cancer. In particular, we identified inhibitors of the Ras
pathway, including ERK and MEK inhibitors (ERKi and MEKi);
compounds related with the cell cycle, such as Aurora inhibitors
(Aurorai), CDK inhibitors (CDKi), and PLK1 inhibitors (PLK1i); an
inhibitor of the chaperone HSP90 (HSP90i); two chemotherapeutic
agents named gemcitabine and docetaxel; and, as expected, several
compounds related with the PI3K pathway, including mTOR
inhibitors (mTORi) and RTK inhibitors (RTKi) (Fig 1B; see
Appendix Table S1 for results with all drugs tested). To test whether
the inhibitors found to decrease TRF1 levels also decreased the
levels of other shelterin components, we studied RAP1 and TIN2
protein levels (Appendix Fig S1A and B). We found that TIN2
protein levels were not affected by any of the compounds found to
decrease TRF1, with the exception of RTKi that increased TIN2
▸Figure 1. Identification of novel compounds with the ability to downregulate TRF1 protein levels.A Experimental procedure: 114 compounds approved by the FDA or in clinical trials are assessed by the Opera High Screening system for their ability to reduce TRF1
protein levels in CHA9.3 lung cancer mouse cells.
B Representative images (top) and quantification (bottom) of TRF1 nuclear fluorescence of patient-derived h676 GSCs cells treated with the indicated compounds for
24 h at 1 lM. Scale bars, 5 lm. Data are representative of n = 3 biological replicates.
C Western blot images (top) and TRF1 protein levels (bottom) of patient-derived h676 GSCs cells treated with the indicated compounds for 24 h at 1 lM. Data are
representative of n = 3 (PLKi, HSP90i, and RTKi) and n = 4 (Aurorai, mTOR, CDKi, docetaxel, gemcitabine, ERKi, MEKi) biological replicates.
D Schematic representation of the novel TRF1 regulatory pathways. Asterisk indicates targets of TRF1 inhibitory compounds found in the screening.
Data information: Data are represented as mean  SEM. n represents biological replicates. Significant differences using unpaired t-test are indicated by *P < 0.05,
**P < 0.01, ***P < 0.001.
Source data are available online for this figure.
2 of 21 EMBO Molecular Medicine 11: e10292 | 2019 ª 2019 The Authors





















































































































DMSO Gem. RTKi PLK1iCDKi
































ª 2019 The Authors EMBO Molecular Medicine 11: e10292 | 2019 3 of 21
Leire Bejarano et al EMBO Molecular Medicine
levels (Appendix Fig S1A). In the case of RAP1, we found a signifi-
cant decrease by MEKi, again docetaxel increased RAP1 protein
levels (Appendix Fig S1B).
To validate the ERK/MEK pathway as a novel signaling pathway
that modulates TRF1 foci formation, we selected 5 structurally dif-
ferent MEK inhibitors and three structurally different ERK inhibitors
(see Materials and Methods) and tested these compounds at 1 lM
during 24 h in the CHA-9.3 mouse lung cancer cell line followed by
TRF1 immunofluorescence analysis. All the MEK and ERK inhibitors
showed a clear inhibition of TRF1 levels (Fig EV1B and C) with the
exception of the ERK inhibitor GDC-0944, which, in fact, did not
inhibit phospho-ERK levels in this cell line, explaining the lack of
effect on TRF1 foci (Fig EV1D). The same chemical biology
approach was used to validate HSP90 and tubulin agents as TRF1
modulators. We tested a total of five structurally different HSP90
inhibitors and three independent taxol derivatives (Materials and
Methods). All of the compounds rendered a significant decrease in
TRF1 foci fluorescence (Fig EV1E and F). In summary, we identify
here new TRF1 regulatory pathways and validate these novel TRF1
modulators by using several chemically diverse inhibitors of these
pathways.
As we previously described that TRF1 inhibition effectively
blocked glioblastoma growth both in mouse models and in xeno-
graft models of patient-derived glioma stem cells (GSCs; Bejarano
et al, 2017), we next tested whether these newly identified TRF1
modulators were also able to downregulate TRF1 protein levels in
patient-derived GSCs. To this end, we treated h676 patient-derived
primary GSCs (Bejarano et al, 2017) with the different compounds
at 1 lM concentration during 24 h and analyzed TRF1 levels by
Western blot. All the compounds, with the exception of Aurora and
PLK1 inhibitors, were able to downregulate TRF1 protein levels in
human GSCs (Fig 1C); thus, we further characterized all the
compounds except for Aurora and PLK1 inhibitors.
In summary, by using an unbiased screening we identified here
several pathways and compounds with the ability to downregulate
TRF1 levels in both lung cancer and glioblastoma cells, including
inhibitors of the Ras pathway (ERK and MEK), the cell cycle-related
CDK inhibitor, the inhibitor of the chaperone HSP90, RTK, and
mTOR inhibitors (Fig 1D), and two chemotherapeutic agents (gemc-
itabine and docetaxel).
Novel TRF1 modulators induce telomeric DNA damage in
cancer cells
Trf1 deletion has been previously shown to induce a persistent DDR
at telomeres in different cell lines, which leads to decreased cell
viability (Martinez et al, 2009; Sfeir et al, 2009). To address
whether the newly identified TRF1 inhibitors were also able to
induce DNA damage specifically at telomeres (the so-called telom-
ere-induced DNA damage foci or TIFs), we treated CHA9.3 lung
cancer cells with all the selected hits for 24 h at 1 lM followed by a
double immunofluorescence of the cH2AX to detect DNA damage
and of the shelterin component RAP1 to mark the telomeres. We
found that all the TRF1 compounds were able to significantly
increase the number of cells with more than 1 TIF, with the excep-
tion of mTOR inhibitors, where the TRF1 decreased did not reach
statistical significance (Fig 2A). Furthermore, when we normalized
the mean number of TIFs per nucleus (Appendix Fig S2A) to total
cH2AX DNA damage (Appendix Fig S2B), we observed that in the
majority of the cases the DNA damage steams from telomeres
(Appendix Fig S2C). Importantly, in patient-derived glioblastoma
stem cells (h676 GSCs), we found that all the TRF1 inhibitors
induced increased global DNA damage as indicated by increased
numbers of cells positive for the cH2AX DNA damage marker
(Fig 2B); however, in this case owing to the fact that these cells
cannot be attached to the plates, we could not perform TIF analysis.
Trf1 inhibition by using genetic deletion has been previously
shown to induce the so-called multitelomeric signals (MTS), which
are associated with increased telomere fragility and increased telom-
ere damage (Martinez et al, 2009; Sfeir et al, 2009). Thus, we next
tested whether our hits had the ability to increase the number of
MTS in h676 patient-derived GSCs. To this end, we treated GSCs
with the different compounds for 24 h at 1 lM and then performed
telomere quantitative fluorescence in situ hybridization (Q-FISH) on
metaphase spreads to visualize telomeres (Materials and Methods).
We found that mTOR inhibitors, MEK inhibitors, and RTK inhibitors
significantly increase the number of MTS (Fig 2C). The rest of the
compounds, namely ERK inhibitors, CDK inhibitors, HSP90 inhibi-
tors, docetaxel, and gemcitabine, completely blocked the formation
of metaphases, and this prevented determination of MTS upon treat-
ment with these compounds. In summary, the newly identified
TRF1 inhibitory compounds recapitulate the telomeric defects asso-
ciated with TRF1 genetic deletion, such as induction of telomeric
DNA damage (TIFs) and induction of telomere fragility (MTS).
Novel TRF1 inhibitors reduce stemness of primary
patient-derived GSCs
We previously demonstrated that TRF1 is overexpressed in both
adult and pluripotent stem cells and it is essential for stemness
(Schneider et al, 2013) and that Trf1 genetic deletion significantly
reduced stemness in both neural stem cells (NSCs) and glioma stem
▸Figure 2. New TRF1 chemical inhibitors induce DNA damage in lung cancer and glioblastoma cells.A Representative images (left) and percentage (right) of cells presenting 1 or more cH2AX and RAP1 colocalizing foci (TIFs) upon treatment of CHA9-3 lung cancer cells
with the indicated compounds. White arrowheads point to colocalization of cH2AX and RAP1. Scale bars, 5 lm. Data are representative of n = 6 (DMSO) and n = 3
(mTORi, PI3Ki, RTKi, MEKi, ERKi, HSPO90i, CDKi, docetaxel) biological replicates.
B Representative images (left) and percentage (right) of cH2AX-positive cells per field in DMSO or compound-treated patient-derived h676 GSCs. Scale bars, 50 lm. Data
are representative of 6 (DMSO) and 3 (mTORi, docetaxel, ERKi, MEKi, RTKi, HSP90i, gemcitabine, CDKi) biological replicates.
C Quantification of multitelomeric signals (MTS) in patient-derived h676 GSC metaphases upon treatment with the indicated compounds. Representative images of the
qFISH in the metaphases (left). Multitelomeric signals are indicated by arrowheads. Scale bars, 1 lm. Data are representative of n = 31 (DMSO), n = 18 (mTORi),
n = 11 (MEKi), and n = 24 (RTKi) biological replicates.
Data information: Data are represented as mean  SEM. Significant differences using unpaired t-test are indicated by *P < 0.05, **P < 0.01, ***P < 0.001.
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cells (GSCs; Bejarano et al, 2017). Thus, we next set to address
whether the novel TRF1 modulators identified here also have the
ability to reduce stemness in two independent patient-derived GSCs,
h676, and h543 cells (Bejarano et al, 2017). To this end, we
performed a dose–response sphere formation assay by plating disag-
gregated cells in a 96-well plate and treated them with the different
compounds at several concentrations (Materials and Methods). We
found that all the compounds had the ability to reduce stemness in
both patient-derived GSC cell lines as indicated by decreased
number of spheres 7 days after plating (Fig 3A–H). It is important
to point out that in these graphs, the data are represented as a
percentage of spheres normalized to the DMSO cells. In addition, we
calculated the growth inhibition 50 (or GI50) for every compound,
which indicates the concentration at which the drug causes the 50%
of reduction in stemness (Table 1). We observed that the most
potent compounds were the HSP90 inhibitor, gemcitabine and doce-
taxel, which had a GI50 ranging between 0.1 and 1.5 nM. They were
followed by mTOR inhibitor, ERK inhibitor, MEK inhibitor, and ERK
inhibitor in which the GI50 was between 0.05 and 0.5 lM, and
finally, the RTK inhibitors showed the highest GI50, ranging
between 1 and 5 lM (Table 1). The fact that the RTK inhibitor,
which strongly decreased TRF1 protein levels 24 h after treatment,
had a high GI50 may be due to a low stability of this compound in
long-lasting experiments. In summary, all the newly identified TRF1
modulators significantly reduce the stemness of two independent
primary patient-derived GSCs lines.
TRF1 is directly phosphorylated by ERK2, mTOR, and bRaf kinases
Next, we set to study the mechanisms by which the newly identified
compounds regulate TRF1 levels. We had previously reported that
the TRF1 telomeric protein is regulated by the PI3K signaling path-
way (Mendez-Pertuz et al, 2017). In particular, TRF1 is directly
phosphorylated by the PI3K downstream target AKT at different
residues (T248, T330, and S344), and this phosphorylation is neces-
sary for TRF1 stability and TRF1 foci formation in vivo (Mendez-
Pertuz et al, 2017). Thus, we first addressed here whether the newly
identified compounds were acting through the PI3K/AKT pathway
by assessing p-AKT levels upon treatment with the different inhibi-
tors. To this end, we treated h676 GSCs with the compounds at
1 lM for 24 h and we checked p-AKT levels by Western blot. From
all the tested compounds, RTKi, mTORi, and HSP90i significantly
downregulated AKT phosphorylation (Appendix Fig S3A). However,
we observed that ERKi, MEKi, CDKi, gemcitabine, and docetaxel did
not affect p-AKT, suggesting that these compounds are acting
through AKT-independent pathways (Appendix Fig S3A).
As the Ras pathway is heavily mutated in cancer, we next set to
explore whether TRF1 is also a direct substrate of different kinases
of the Ras pathway—including ERK, MEK, and bRaf kinases. In
parallel, we also tested whether TRF1 was a target of the mTOR
kinase, also found here to modulate TRF1 (Fig 1A and B). To this
end, we carried out in vitro kinase assays with affinity-purified
mouse GST-TRF1 incubated with either mouse-purified ERK2,
mouse-purified MEK1, human-purified bRaf, or human-purified
mTOR, always in the presence of [c-32P]ATP (Materials and Meth-
ods). Importantly, ERK2 and bRaf but not MEK yielded a clear TRF1
phosphorylation signal (Fig 4A–D). Interestingly, an oncogenic
mutant of bRaf (V600E; Davies et al, 2002) triggered a significantly
higher TRF1 phosphorylation compared to the wild-type bRaf kinase
(Fig 4C), thus suggesting a potentially important role of the bRaf
kinase in TRF1 regulation in cancer.
Next, we studied the specificity of these phosphorylation signals
by using specific inhibitors of these kinases. We observed that TRF1
phosphorylation by ERK2 was decreased in the presence of ERK
inhibitors but not MEK inhibitors (Fig 4E). Similarly, TRF1 phos-
phorylation by bRaf was inhibited in the presence of the bRaf inhibi-
tors vemurafenib and dabrafenib (Fig 4F). Regarding mTOR kinase,
we observed a TRF1 phosphorylation signal which was decreased in
the presence of the TRF1 inhibitor Ku007694 but not in the presence
of rapamycin, in agreement with the fact that rapamycin acts
through FKBP12 (Fig 4G and H).
We next set to identify the specific TRF1 phosphorylation sites
by ERK2, bRaf (WT and V600E), and mTOR kinases. To this end,
we analyzed phosphopeptides by liquid chromatography–mass
spectrometry (LC/MS/MS) analysis in TRF1, TRF1&ERK2,
TRF1&bRAFWT, TRF1&bRAFV600E, and TRF1&mTOR samples
containing ATP (Materials and Methods). Interestingly, we identi-
fied 13 different TRF1 phosphopeptides in samples containing
ERK2, including T4, S6, S7, T44, T195, T268, T270, T274, T298,
T328, T330, T335, and T358 (Fig 4I). Additionally, we identified
four different TRF1 phosphopeptides in samples containing RAFWT
and bRAFV600E, including T4, T298, T330, and T336 (Fig 4J). Inter-
estingly, the signal of the phosphopeptides was higher in the pres-
ence of the mutant form of bRAF (bRAFV600E) (Fig 4J), again
suggesting a potentially important role of TRF1 modification by
bRAF in cancer. In the case of the mTOR kinase, we identified 13
different residues, including T4, S6, S7, T44, S176, S236, T241,
T268, S301, S319, T330, S352 (Fig 4K). As expected, no phospho-
peptides were identified in the sample containing only TRF1
(Fig 4I–K). Out of the identified phosphorylation sites (Fig 4L), we
decided to focus in the ERK2-dependent phosphosites for further
analysis as this kinase is downstream in the Ras pathway and is also
AKT independent (Appendix Fig S3A). Future studies warrant
further analysis on the role of mTOR and bRaf kinases in TRF1
regulation.
For the in vitro validation of the ERK phosphorylation sites, we
generated the GST-tagged Trf1 alleles T44, T195, T298, and T358 as
singles mutants and T4/S6/S7, T268/T270/T274, and T328/T330/
T335 as triple mutants. In all the cases, threonine or serine was
mutated to alanine. The affinity-purified GST-TRF1 WT or mutant
alleles were incubated with mouse-purified ERK2 always in the pres-
ence of [c-32P]ATP. We found significantly decreased TRF1 phos-
phorylation levels in the variants harboring T4/S6/S7, T44, T268/
T270/T274, and T328/T330/T335 substitutions compared to wild-
type TRF1 (Fig 4M). We extended this analysis with additional
TRF1 single mutants in ERK-phosphorylation sites, such as T328A,
T330A, and T335A (Fig 4N), all of which resulted in decreased ERK-
dependent TRF1 phosphorylation. Furthermore, we demonstrate
that, among the AKT-dependent phosphosites of TRF1, S344 (T358
in human) is as also a target for ERK-mediated phosphorylation
(Fig 4O). As negative control, we also generated a TRF1 phospho-
mutant in residue T248 whose phosphorylation is mediated by AKT
but not ERK (Fig 4O; Mendez-Pertuz et al, 2017). As expected, this
mutant did not result in decreased TRF1 phosphorylation (Fig 4O).
Importantly, in order to address the in vivo role of TRF1 modifi-
cations by ERK2, eGFP-tagged Trf1 wild-type and mutant alleles
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Figure 3. New TRF1 inhibitory compounds reduce stemness in patient-derived glioma stem cells.
A–H Dose–response curves of h543 and h676 patient-derived GSCs treated with the indicated compounds at several concentrations. Data are representative of n = 2
biological replicates. Data are represented as mean  SEM normalized to DMSO.
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were transduced into p53-deficient Trf1lox/lox MEFs (Fig 5A) and we
determined nuclear eGFP spot fluorescence, as an indication of the
ability of the different eGFP-TRF1 mutant proteins to localize to
telomeres. From the 13 possible phosphosites, T44, T195, T298, and
T358 were generated as single mutants, whereas T4/S6/S7, T268/
T270/T274, and T328/T330/T335 were assessed as tripe mutants
(Fig 5A). In order to discard possible interference of the eGFP-
tagged TRF1 alleles with the endogenous TRF1, MEFs were trans-
duced with Cre recombinase to induce endogenous Trf1 deletion.
Overexpression of eGFP-Trf1 alleles and endogenous Trf1 deletion
were confirmed by Western blot analysis using a specific TRF1 anti-
body (Fig 5B). Quantification of nuclear eGFP spot fluorescence in
Trf1/ MEFs showed that the triple mutant T328/T330/T335 was
the only mutant which showed a significant decrease in the intensity
of TRF1 telomeric foci compared to MEFs expressing wild-type
TRF1 (Fig 5C). In contrast, no significant differences were detected
between the rest of the mutants (T44, T195, T298, T358, T4/S6/S7,
T268/T270/T274) and wild-type TRF1 (Fig 5C; see representative
images in Fig EV2). TRF1 deficiency is associated with severe
defects in cell proliferation (Martinez et al, 2009; Sfeir et al, 2009).
In order to address in vivo whether the different TRF1 mutants were
able to rescue the proliferation defects of Trf1-deficient MEFs, we
assess the growth rate of Trf1-deficient MEFs expressing the dif-
ferent eGFP-tagged Trf1 wild-type or mutant alleles. All the single
mutants were able to completely or almost completely rescue the
proliferation defects associated with Trf1 deficiency (Fig 5D). We
next assessed the triple mutants (T4/S6/S7, T268/T270/T274, and
T328/T330/T335), and, in agreement with eGFP-TRF1 telomeric foci
findings (Fig 5C), we observed that the triple mutant TRF1-T328/
T330/T335 showed the more severe proliferation defects (Fig 5D).
Thus, we decided to study the effect of each of the single mutants
TRF1-T328, TRF1-T330, and TRF1-T335 separately by transducing
the mutant alleles into Trf1lox/lox MEFs, followed by Cre recombi-
nase transduction to induce endogenous Trf1 deletion. Overexpres-
sion of eGFP-Trf1 alleles and endogenous Trf1 deletion were
confirmed by Western blot analysis using a specific TRF1 antibody
(Fig 5E). Quantification of eGFP-TRF1 nuclear fluorescence revealed
that the mutant TRF1-T330 and, in a lesser extent, the mutant TRF1-
T335 showed a decrease in the intensity of TRF1 telomeric foci
compared to MEFs expressing wild-type TRF1 (Fig 5F; see represen-
tative images in Fig EV2). Interestingly, out of the three mutants,
the TRF1-T330 showed the more severe proliferation defects
(Fig 5D). Next, we plotted the proliferation results in parallel and
calculated the statistical significance for the different eGFP-TRF1
proteins (Appendix Fig S4). Albeit all the mutants showed a partial
rescue of the proliferation defects, mutants T330A and T335A
resulted in a significantly lower proliferation rate compared with
wild-type GFP1-TRF1 (Appendix Fig S4). It is important to point out
that T330 phosphosite is also essential for AKT-mediated TRF1
phosphorylation (Mendez-Pertuz et al, 2017).
Importantly, we next set to address whether we could rescue the
telomere damage phenotype induced by ERKi by overexpressing
wild-type eGFP-TRF1 or different TRF1 mutants. To this end, we
overexpressed WT TRF1-eGFP and non-phosphorylatable mutant
versions of TRF1 in MEFs treated or not with the ERKi (Fig 5G). In
all cases, treatment with the ERKi decreased the levels of wild-type
or mutant eGFP-TRF1 proteins (Fig 5G). Interestingly, the induction
of TIFs as the result of ERK1/2 inhibition can be reduced by twofold
when overexpressing eGFP-Trf1 WT (Fig 5H) but not when overex-
pressing the mutant versions of GFP-TRF1 (both single and triple
TRF1 mutants in ERK1/2 phosphosites T328, T330, and T335;
Fig 5H), which showed significantly higher amounts of TIFs which
were comparable to that observed in control lines treated with ERKi
(Fig 5H). These results indicate that the telomere defects induced by
ERKi are mediated by TRF1 phosphorylation.
Next, to provide direct evidence for a role of ERK1/2 in TRF1
regulation, we genetically depleted ERK1/2 kinase in MEFs and
analyzed TRF1 protein levels both by Western blot and nuclear







HSP90i (Geldanamycin) ETP-50853 0.15 0.25
Docetaxel ETP-45335 0.24 0.46
Gemcitabine ETP-45337 1.25 0.5
mTORi ETP-50537 433 125
ERKi ETP-50728 218 354
MEKi ETP-51677 61 90
CDKi ETP-47306 164 86
RTKi (Dasatinib) ETP-51801 4,400 913
▸Figure 4. ERK2, bRaf, and mTOR kinases phosphorylate TRF1 in vitro.A–D 1 or 2 lM of GST or GST-TRF1 was incubated with the indicated concentrations of mouse ERK2 kinase (A), human BRaf kinase (WT or V600E) (B, C), or mouse
MEK1 kinase (D) in the presence of 5 lCi [c-32P]ATP. The mixture was resolved by SDS–PAGE followed by autoradiography.
E 1 lM of GST-TRF1 and 0.2 lM of mouse ERK2 kinase were incubated in the presence of ERK and MEK inhibitors.
F 2 lM of GST-TRF1 and 0.1 lM of human BRaf kinase were incubated in the presence of the bRaf inhibitors dabrafenib and vemurafenib.
G, H 1 or 2 lM of GST or GST-TRF1 was incubated with the indicated concentrations of human mTOR kinase (G) in the presence of the mTOR inhibitors rapamycin and
Ku0063794 (H).
I–K Phosphopeptide peak intensity normalized to total TRF1 signal in samples containing only TRF1 or TRF1 plus ERK2 (I), TRF1 plus bRAFWT or bRAFV600E (J), and TRF1
plus mTOR (K); data are representative of n = 2 independent experiments.
L Schematic representation of TRF1 protein with the phosphorylation sites by ERK2, bRAF, mTOR, and AKT.
M–O Representative image (down) and quantification (up) of in vitro phosphorylation assays with the indicated GST-TRF1 wild-type or mutated forms in the presence
of mouse ERK2 kinase. Data are representative of n = 4 independent experiments.
Data information: Data are represented as mean  SEM. Significant differences using unpaired t-test are indicated by *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
Source data are available online for this figure.
8 of 21 EMBO Molecular Medicine 11: e10292 | 2019 ª 2019 The Authors


























5 25 100 5 25 100 ERK2 [nM]









w/o  60    30    15     60    30    15  mTOR [nM]
pmTOR
GST 1uM         GST-TRF1 1uM       GST-TRF1 1uM ; ERK2 0.1uM
ERKi (uM) MEKi (uM)
w/o 1 2 5 10 1 2 5 10w/o
GST-TRF1 [2uM] , BRAF [0.1uM]     















GST-TRF1 [2uM] , mTOR [60nuM]     































































BRAF [0.1uM]     
WT V600E
GST 1uM         
100 10 1 w/o 100 10 1























































































































WT   T248  T330  S344  T330
S344      
75K














































ª 2019 The Authors EMBO Molecular Medicine 11: e10292 | 2019 9 of 21



































































































































TRF1lox/lox MEFs + Cre
Quantification of GFP 











































































































10 of 21 EMBO Molecular Medicine 11: e10292 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Leire Bejarano et al
TRF1 fluorescence. We found that stable RNAi-mediated downregu-
lation of ERK1/2 kinases resulted in a significant decrease in TRF1
protein levels (Fig 6A) as well as in TRF1 foci fluorescence
compared to controls with a scrambled oligo (Fig 6B), thus demon-
strating that genetic ERK depletion recapitulates the effects of chemi-
cal ERK inhibitors on TRF1.
Finally, we overexpressed eGFP-tagged versions of TRF1 WT, as
well as single and triple TRF1 mutants in T328, T330, and T335 resi-
dues (Fig 6C and D). As expected, we found that stable RNAi-
mediated downregulation of ERK1/2 kinases resulted in a significant
decrease in TIFs (Fig 6E) compared to controls with a scrambled oligo
(Fig 6B). Interestingly, the induction of TIFs as the result of ERK1/2
genetic downregulation was reduced to control levels when overex-
pressing eGFP-Trf1 WT (Fig 6E) but not when overexpressing the
mutant versions of GFP-TRF1 (both single and triple TRF1 mutants in
ERK1/2 phosphosites T328, T330, and T335) (Fig 6E), which showed
significantly higher amounts of TIFs which were comparable to that
observed in control lines treated with ERKi (Fig 6E). These results
indicate that the telomere defects induced by ERK1/2 genetic down-
regulation are mediated by TRF1 phosphorylation.
Combinatory treatments to avoid resistance to TRF1 inhibition
in cancer
Finding novel TRF1 inhibitors not only is interesting to understand
TRF1 biology but also to design rational combinatory treatments to
more effectively inhibit TRF1 levels in cancer and avoid appearance
of resistance mechanisms.
In this regard, it is known that the bad prognosis of glioblas-
toma is mainly due to the existence of a group of cells with stem-
like properties, also known as glioma stem-like cells (GSCs; Singh
et al, 2004). These cells develop resistance to the treatments and
are able to recapitulate the whole tumor, causing a strong recur-
rence (Bao et al, 2006). To model this phenomenon in mice, we
injected patient-derived h676 and h543 GSCs into nude mice and
treated them orally with our ETP-47037 PI3K inhibitor, previously
shown by us to be a potent inhibitor of TRF1 foci ETP-47037
(Bejarano et al, 2017). One week after GSC injection, mice
received oral administration of the vehicle as placebo or of the
ETP-47037 inhibitor 5 days/week, every week until human end-
point, and tumors were continuously followed up by caliper
measurements. Treatment with the PI3K inhibitor ETP-47037
significantly slowed tumor growth in both h543 and h676 xeno-
grafts (Fig EV3A and B), in agreement with our previous findings
(Bejarano et al, 2017). However, tumors became resistant approxi-
mately 1 month after treatment with the ETP-47037 inhibitor and
grew until they reached the human end-point (Fig EV3A and B).
To check whether the PI3K pathway was inhibited in these resis-
tant tumors, we checked p-AKT and p-S6 levels by Western blot in
h543 xenografts but we did not observe any changes between
ETP-47037 and control treated mice (Fig EV3C), indicating that
these tumors are able to reactivate PI3K pathway. In agreement
◀ Figure 5. Phosphorylation of TRF1 residue T330 stabilizes TRF1 telomeric foci in vivo.A Trf1lox/lox p53/ MEFs were transduced with eGFP-tagged Trf1 WT or mutant alleles to overexpressed TRF1 depicted variants. Endogenous TRF1 was deleted by
transduction with Cre recombinase. Opera High Content Screening (HCS) system was used to quantify the GFP spot intensity per cell.
B Western blot images of Trf1lox/lox MEFs with or without overexpression of eGFP-Trf1 WT or mutant alleles followed by Cre recombinase transduction.
C Quantification of eGFP-TRF1 inhibition in Trf1D/D MEFs transduced with eGFP-Trf1 WT or mutant alleles as indicated. Data are representative of n = 15 biological
replicates
D Growth curves of Trf1D/D MEFs transduced with eGFP-Trf1 WT or mutant alleles as indicated. Data are representative of n = 5 biological replicates
E Western blot images of Trf1lox/lox MEFs with or without overexpression of eGFP-Trf1 WT or mutant alleles followed by Cre recombinase transduction.
F Quantification of eGFP-TRF1 inhibition in Trf1D/D MEFs transduced with eGFP-Trf1 WT or mutant alleles as indicated. Data are representative of n = 5 biological
replicates
G Western blot images of p53/ MEFs with or without overexpression of eGFP-Trf1 WT or mutant alleles followed treatment with ERKi. Data are representative of
n = 2 biological replicates
H Representative images (above) and percentage (bottom) of telomeric and 53BP1 colocalizing foci (TIFs) per cells of p53/ MEFs with or without overexpression of
eGFP-Trf1 WT and the indicated mutants upon treatment with the ERKi. White arrowheads: colocalization of telomeric and 53BP1. Scale bars, 10 lm. Data are
representative of n = 2 independent experiments.
Data information: Data are represented as mean  SEM. Significant differences using unpaired t-test are indicated by *P < 0.05, ***P < 0.001.
Source data are available online for this figure.
▸Figure 6. Genetic model of the telomeric role of ERK1/2-mediated TRF1 phosphorylation.A Western blot image (above) and quantification (bottom) of TRF1 protein levels upon genetic depletion of ERK1/2 in p53/ MEF line. Data are representative of n = 3
independent experiments.
B Representative images (above) and quantification (bottom) of TRF1 telomeric foci in ERK1/2 RNA interfered p53/ MEFs. Scale bars, 5 lm. Data are representative of
n = 2 independent experiments.
C p53/ MEFs were sequentially transduced with lentiparticles encoding short hairpins against ERK1/2 and retroparticles for eGFP-tagged Trf1 WT or mutant alleles to
overexpress TRF1-depicted variants in the absence of ERK1/2.
D Western blot image of eGFP-tagged and endogenous TRF1 protein levels upon genetic depletion of ERK1/2 in p53/ MEF line.
E Representative images (above) and percentage (bottom) of telomeric and 53BP1 colocalizing foci (TIFs) per cell in p53/ MEF with or without overexpression of
eGFP-Trf1 WT and indicated mutants upon genetic depletion of ERK1/2. White arrowheads: colocalization of telomeric and 53BP1. Scale bars, 10 lm. Data are
representative of n = 2 biological replicates.
Data information: Data are represented as mean  SEM. Significant differences using unpaired t-test are indicated by *P < 0.05, **P < 0.01.
Source data are available online for this figure.
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with this, TRF1 immunofluorescence and Western blot analysis
revealed that resistant tumors also had similar TRF1 levels than
control tumors (Fig EV3D and E), suggesting that TRF1 re-expres-
sion was associated with tumor re-growth.
Thus, to more effectively block TRF1 expression and avoid resis-
tance to individual drug treatments, we performed drug combina-
tion studies in GSCs in order to design new combinatory treatments
based on TRF1 inhibition. In particular, we tested whether the PI3K
inhibitors, already known to modulate TRF1, could show synergic
effects with the compounds identified here, namely MEKi, ERKi,
RTKi, CDKi, HSP90i, docetaxel, gemcitabine, and mTORi. To assess
possible synergic effects between the different compounds, we used
the GI50 (Table 1) as a reference point and designed a combinato-
rial matrix using different concentrations of the compounds (e.g.,
2 × EC50, EC50, and ½ EC50), studying all the possible combinations.
Combination index is calculated to establish whether the combina-
tion is synergistic, additive or antagonistic, using the Chou–Talalay
method (Chou, 2010). The lower combinatorial index indicates a
better synergic effect between the compounds. Based on this combi-
natorial index, we selected the best combinations for further valida-
tions (Table 2). In particular, we selected the combination of PI3K
inhibitors MEKi, ERKi, RTKi, HSP90i, docetaxel, and gemcitabine
(Table 2). On the other hand, the combination of PI3Ki with mTOR
and CDKi was excluded, as we did not see synergistic effects of the
combination (Fig EV4A and B).
We further validated these synergic effects by performing a
sphere formation assay treating the cells for one week with the
selected concentrations (Table 2). Both number of spheres and the
diameter of the spheres revealed that PI3Ki had significant synergic
effect with MEKi, ERKi, RTKi, HSP90i, docetaxel, and gemcitabine
(Figs 7A–F and EV4C–H).
We next set to address whether those compounds which showed
the best synergic effect in combination with the PI3K inhibitors were
also able to synergistically reduce TRF1 protein levels. To this end,
we treated the patient-derived h676 GSCs with the single agents or
the combinations and we quantified total TRF1 levels by Western
blot. We observed a clear decrease in TRF1 protein levels when we
combined PI3Ki with RTKi, MEKi, or gemcitabine (Fig 7G,I,K). We
also observed a minor decrease upon combination of PI3Ki with
ERKi or HSP09i (Fig 7H and J). However, we did not observe a
significant reduction in TRF1 protein levels upon combination of
PI3Ki and docetaxel (Fig 7L).
Combination of PI3K inhibitors with MEK inhibitors, docetaxel,
and gemcitabine synergistically reduces xenograft growth of
patient-derived GSCs
We next set to address whether the drug combination shown to
synergistically decrease TRF1 levels in vitro was also able to syner-
gize in vivo in human patient-derived xenograph models.
To this end, we injected primary patient-derived GCSs (h676)
cells subcutaneously into nude mice and treated them with orally or
IP administered compounds, as single agents or in combination with
the PI3K inhibitor ETP-47037. One week after h676 GSCs injection,
mice received oral or IP administrations as follows: (i) the PI3K inhi-
bitor was orally administrated 5 days/week at a concentration of
50 mg/kg, until the human end-point; (ii) the MEK inhibitor
PD0325901 was orally administrated 5 days/week at a concentra-
tion of 3 mg/kg, until the human end-point; (iii) the ERK inhibitor
was orally administrated 5 days/week at a concentration of 50 mg/
kg, until the human end-point; (iv) the RTK inhibitor Dasatinib was
orally administrated 3 days/week at a concentration of 30 mg/kg,
until the human end-point; (v) gemcitabine was intraperitoneally
administrated at a concentration of 125 mg/kg, once a week, until
the human end-point; (vi) docetaxel was intraperitoneally adminis-
trated at a concentration of 7.5 mg/kg, twice a week, until the
human end-point; (vii) the HSP90 inhibitor was orally administrated
3 days/week at a concentration of 60 mg/kg, until the human end-
point (see Materials and Methods). Note that all the listed
compounds were administrated alone, or in combination with the
PI3K inhibitor ETP-47037 and tumor growth was always compared
to the placebo group.
Among all the possible combinations, the combination of the
PI3K inhibitor ETP-47037 with ERKi, RTKi, and HSP90i resulted
toxic in early stages of the treatment (Appendix Fig S5A), although
we observed a synergism with ERKi (Fig 8A). On the other hand,
the rest of the combinations—PI3Ki with MEKi, gemcitabine, and
docetaxel—were well tolerated by the mice. In addition, tumor
follow-up revealed that the PI3K inhibitor ETP-47037 also showed
significant synergic effect with MEKi, gemcitabine, and docetaxel
(Fig 8B–D), but not with RTKi or HSP90i (Appendix Fig S5B and C).






PI3Ki + HSP90i (Geldanamycin) 0.2–0.4 0.005
PI3Ki + docetaxel 0.2–0.4 0.001
PI3Ki + gemcitabine 0.2–0.4 0.006
PI3Ki + ERKi 0.2–0.4 0.3
PI3Ki + MEKi 0.2–0.4 0.24
PI3Ki + RTKi (Dasatinib) 0.2–0.4 10
▸Figure 7. In vitro combinatorial studies of PI3Ki with novel TRF1 inhibitory compounds.A–F Representative images (left) and quantification (right) of number of spheres formed by patient-derived h676 GSCs 7 days after treatment with the indicated
compounds as single agents or in combination. Scale bars, 100 lm. Data are representative of n = 6 biological replicates.
G–L Western blot images (left) and TRF1 protein levels (right) measured in patient-derived h676 GSCs 24 h after treatment with the indicated compounds as single
agents or in combination. Data are representative of n = 3 (combination in K), n = 4 (combination in G, L), n = 5 (RTKi in G, combination in H–J, docetaxel in L),
n = 6 (DMSO in G–L, and ERKi in H), n = 11 (PI3Ki in G–J, L) biological replicates.
Data information: Data are represented as mean  SEM. Significant differences using unpaired t-test are indicated by *P < 0.05, **P < 0.01, ***P < 0.001.
Source data are available online for this figure.
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We next set to address TRF1 levels in those combinations which
showed a positive synergic effect, i.e., PI3Ki with ERKi, MEKi, gemc-
itabine, and docetaxel. We performed TRF1 immunofluorescence
analysis in tumor samples treated with vehicle, single agents, or
double agents. As shown here, long-term PI3Ki-treated tumors did
not present a reduction in TRF1 levels (Fig 8E–H). In contrast, we
observed a clear decrease in TRF1 nuclear fluorescence when the
tumors were treated with combinations of PI3Ki and either ERKi or
MEKi (Fig 8E–F), again demonstrating that these pathways modu-
late TRF1 levels independently. In the case of PI3Ki combination
with docetaxel, we also observed a significantly lower TRF1 levels
with the dual treatment (Fig 8G). However, docetaxel alone was
also able to induce a strong decrease in TRF1 levels compared to
vehicle-treated tumors (Fig 8G). Finally, the gemcitabine was not
able to decrease TRF1 level neither alone nor in combination with
PI3Ki (Fig 8H).
Discussion
Telomere maintenance above a minimum length is essential to
achieve an unlimited replicative potential, which makes telomere
maintenance indispensable for the growth of cancer cells. In fact,
more than 90% of human tumors aberrantly overexpress telomerase
(Kim et al, 1994; Shay & Bacchetti, 1997; Joseph et al, 2010), while
the remaining telomerase-negative tumors activate ALT (Bryan
et al, 1997; Barthel et al, 2017). Thus, multiple studies have focused
in telomeres as potential anti-cancer targets. In this regard, the most
advanced compound is the telomerase inhibitor GRN163L, also
known as Imetelstat (Harley, 2008; Joseph et al, 2010). However,
telomerase inhibition in mouse models and in human clinical trials
has shown some limitations, most likely due to the fact that a telom-
erase abrogation would only affect critically short telomeres, and
tumors are heterogeneous in terms of telomere length (Chin et al,
1999; Greenberg et al, 1999; Gonzalez-Suarez et al, 2000; Parkhurst
et al, 2004; Perera et al, 2008; Middleton et al, 2014).
Interestingly, not only telomerase, but also shelterin components
are frequently altered in cancer. Our group and others have recently
described that the TRF1-interacting protein POT1 is often mutated in
familiar glioblastoma cases as well as other tumor types (Newey
et al, 2012; Ramsay et al, 2013; Robles-Espinoza et al, 2014; Shi
et al, 2014; Zhang et al, 2014; Bainbridge et al, 2015; Calvete et al,
2015). Also, we had recently reported that TRF1 is significantly
upregulated in both mouse and human glioblastoma tumor samples
(Bejarano et al, 2017). More importantly, we showed that TRF1
genetic deletion significantly impairs tumor growth in both
p53-deficient K-RasG12V-induced lung tumors and glioblastoma
mouse models, in a manner that is independent of telomere length
(Garcia-Beccaria et al, 2015; Bejarano et al, 2017). These facts high-
light the possibility of alternative therapies to telomerase inhibition
to impair telomere capping in cancer, by directly inhibiting the
TRF1 shelterin component.
However, the mechanisms of TRF1 regulation in cancer are still
poorly understood. In addition, novel compounds with the ability to
downregulate TRF1 levels need to be developed. On this matter, our
group performed an initial screening with the aim of identifying
molecules and novel signaling pathways that modulate TRF1 bind-
ing to telomeres (Garcia-Beccaria et al, 2015). We identified several
compounds which belonged to the PI3K family (Mendez-Pertuz
et al, 2017). In particular, we found that both PI3K and AKT inhibi-
tors significantly reduced TRF1 telomeric foci and this caused
increased telomeric DNA damage and fragility (Mendez-Pertuz et al,
2017). Additionally, we found that TRF1 is phosphorylated at resi-
dues T248, T330, and S344 by AKT and that these modifications
regulate TRF1 foci formation in vivo (Mendez-Pertuz et al, 2017).
These findings uncovered an important functional connection
between the Pi3K pathway and TRF1 regulation, thus connecting
two of the major pathways in cancer and aging, namely telomeres
and the Pi3K pathway (Mendez-Pertuz et al, 2017).
In order to identify additional signaling pathways that modulate
TRF1 binding to telomeres, here we screened a CNIO collection of
114 anti-tumoral drugs, which are either FDA-approved or in clinical
trials and which cover 20 of the 26 pathways included in Reactome
database (see Materials and Methods). We identify novel drugs that
can inhibit TRF1 in both lung cancer and glioblastoma cells, includ-
ing inhibitors of some of the most deregulated pathways in cancer,
namely, the Ras pathway (ERKi and MEKi), the cell cycle-related
CDK inhibitor, the inhibitor of the chaperone HSP90, two
chemotherapeutic agents (gemcitabine and docetaxel), and RTK and
mTOR inhibitors. We show here that these drugs recapitulate the
effects of Trf1 genetic deletion, including DNA damage induction,
telomere fragility, and reduction of stemness. Importantly, some of
these drugs act independently of the Pi3K pathway, i.e., the Ras
pathway components ERKi and MEKi, CDKi, gemcitabine, and
docetaxel, underlying the importance of telomere capping for cancer
cells.
We further demonstrate a role of the Ras pathway in regulating
telomere protection. In particular, we show that both ERK2 and bRaf
are able to phosphorylate TRF1 in vitro. Furthermore, we identify
here 13 possible sites for TRF1 phosphorylation by ERK2, as well as
four different putative sites for TRF1 phosphorylation by bRaf. As
the ERK2 kinase is a downstream component of the pathway, we
▸Figure 8. In vivo combinatorial studies of PI3Ki with novel TRF1 inhibitory compounds in patient-derived GBM xenograft models.A–D Longitudinal tumor growth follow-up in mice injected with patient-derived h676 GSCs and treated with the indicated compounds in single agents or combination.
n represents number of tumors, in (A): vehicle n = 16, PI3Ki n = 8, ERKi n = 16, combination n = 8; in (B): vehicle n = 16, PI3Ki n = 16, MEKi n = 8, combination
n = 8; in (C): vehicle n = 8, PI3Ki n = 16, docetaxel n = 16, combination n = 8; in (D): vehicle n = 16, PI3K n = 16, gemcitabine n = 4, combination n = 4. P-values
represent the mean of all the time points.
E–H Representative images (top) and quantification (bottom) of TRF1 nuclear fluorescence in tumors treated with the indicated compounds as single agents or in
combination. Scale bars, 10 lm. Data are represented as mean  SEM. n represents number of tumors: in (E): vehicle n = 15, PI3Ki n = 10, ERKi n = 8,
combination n = 2; in (F): vehicle n = 15, PI3Ki n = 10, MEKi n = 8, combination n = 6; in (G): vehicle n = 15, PI3Ki n = 10, docetaxel n = 8, combination n = 4;
in (H): vehicle n = 15, PI3K n = 10, gemcitabine n = 8, combination n = 6.
Data information: Significant differences using unpaired t-test with Welch’s correction are indicated by *P < 0.05, **P < 0.01, ***P < 0.001.
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further studied the in vivo role of the 13 possible phosphosites and
showed that the mutation of T330 has a determinant role in TRF1
foci formation in vivo. Importantly, T330 is also phosphorylated by
AKT (Mendez-Pertuz et al, 2017), bRaf, and mTOR kinases, suggest-
ing that this site may be key residue for TRF1 modulation by dif-
ferent kinases. These unprecedented findings are in agreement with
previous observations that ERK genetic deletion causes a reduction
of TRF1 levels in embryonic stem cells (ES cells; Chen et al, 2015),
as well as that TRF2, another shelterin protein, is targeted by ERK1/
2 (Picco et al, 2016). Future studies warrant understanding regula-
tion of other shelterin components throughout these and other post-
transcriptional modifications. Interestingly, a previous study also
showed that Ras overexpression can protect cancer cells from telom-
ere dysfunction (Biroccio et al, 2013).
Finally, in the present work we use these new TRF1 regulatory
pathways as a rational to discover novel drug combinations based on
TRF1 inhibition, which effectively block resistance to individual
drugs. In particular, it is known that the bad prognosis of many tumor
types including glioblastoma is mainly due to the existence of a group
of cells with stem-like properties, also known as glioma stem-like
cells (GSCs; Singh et al, 2004). These cells develop resistance to the
treatments and are able to recapitulate the whole tumor, causing a
strong recurrence (Bao et al, 2006). By using patient-derived GSC
xenograft models, here we show synergic effects of PI3K inhibitors,
previously shown by us to inhibit TRF1 levels (Mendez-Pertuz et al,
2017), with ERKi, MEKi, gemcitabine, and docetaxel. In the case of
gemcitabine, we observed differential effects in vitro and in vivo,
which could be due to TRF1-independent effects of this drug.
In summary, here we describe that key cancer pathways, such as
the Ras pathway, are important regulators of telomere capping
through post-transcriptional modification of the shelterin component
TRF1, essential for telomere protection. Furthermore, we demonstrate
that these findings provide a new rational for the design of new
combinatorial therapies based on TRF1 inhibition in cancer.
Materials and Methods
Mice
For xenograft experiments, 8-week athymic nude females were
obtained from Harlan (Foxn1nu/nu). Mice were maintained at the
Spanish National Cancer Centre (CNIO) in accordance with the
recommendations of the Federation of European Laboratory Animal
Science Associations (FELASA) under specific pathogen-free condi-
tions. All animal experiments were performed in accordance with
the guidelines stated in the International Guiding Principles for
Biomedical Research Involving Animals, developed by the Council
for International Organizations of Medical Sciences (CIOMS), and
were approved by the Ethical Committee (CEIyBA) from the CNIO.
Along with those guidelines, mice were monitored in a daily or
weekly basis and they were sacrificed in CO2 chambers when the
human end-point was considered.
Cell culture and transfection
Mycoplasma-free patient-derived glioma stem cells (h543 and h676)
were cultured in neurosphere medium from NeuroCult (Stem Cell
Technologies Inc, Vancouver, Canada) supplemented with 20 ng/ml
basic-FGF (RD Systems) and 10 ng/ml EGF (Gibco).
Mycoplasma-free Trf1lox/lox p53/ MEFs and K-RasD/LG12Vgeo
p53/ tumor-derived CHA-9-3 cell line were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS). All cell lines and
primary cultures were regularly tested mycoplasma-free.
For retroviral infection, supernatants were produced in 293T cells
transfected with the ecotropic packaging plasmid pCL-Eco, the
envelope plasmid pCMV-VSV-G and either pBabe-Cre and/or eGFP-
TRF1 pWzl-Hygro (a gift from T. de Lange, Addgene plasmid #19834)
using Fugene transfection reagent. Two days later, retroviral super-
natants were collected and Trf1lox/lox p53/ MEFs were infected with
the corresponding retroviral supernatant at 12-h intervals.
For lentiviral infection, supernatants were produced in 293T cells
transfected with the envelope plasmid pCMV-VSV-G, the ecotropic
packaging plasmid psPAX2 and either pLKO.1 empty and/or pLKO.1
vectors expressing short hairpin RNA for either ERK1 or ERK2
(SIGMA) using Fugene transfection reagent. Two days later, lentivi-
ral supernatants were collected and p53/ MEFs were infected with
the corresponding lentiviral supernatant at 12-h intervals.
Screening of compounds
We tested 114 compounds belonging to a library of approved anti-
tumoral drugs or in clinical phases to identify drugs that modulate
TRF1 levels at telomere. The library covers 80% of the pathways
described in Reactome. The number of inhibitors for each pathway
was the following: cell cycle (2), cell–cell communication (10),
cellular response to external stimuli (11), chemotherapeutics (2),
DNA repair (2), extracellular matrix reorganization (3), gene expres-
sion (12), hemostasis (16), immune system (20), metabolism
proteins (2), organelle biogenesis and maintenance (1), and signal
transduction (26).
CHA-9-3 lung tumor cells were treated 24 h at 1 lM with the
library of compounds, and TRF1 levels were assessed by
immunofluorescence (See description below). For quantitative
measurement of TRF1 foci levels, pictures of fixed cells were auto-
matically acquired from each well by the Opera High Content
Screening (HCS) system (Perkin Elmer).
The novel TRF1 modulators identified in the screening of











We also tested the following compounds:
ERKi: GDC-0994, VRT752271
MEKi: Trametinib Cobimetinib PD-0325901 TAK-733
HSP90i: Debio_0932, 17-AAG, NVP-AUY922, NVP-HSP990
Taxol derivatives: ABT_751(E706), paclitaxel
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Phosphorylation assays
The GatewayTM technology (Thermo Fisher Scientific) was used
to clone the full-length mouse TRF1 into the expression vector
pDEST565, which adds two tags (6xHis and GST) at the N termi-
nus of the encoded protein. Protein was expressed in Escherichia
coli strain BL21(DE3), followed by purification with affinity chro-
matography using a Ni2+ column (HisTrap FF crude, 17-5286-01,
GE Healthcare) in an AKTA Prime system (GE Healthcare), and dial-
ysis against 20 mM phosphate buffer pH 7.5, 200 mM NaCl, 2 mM
TCEP.
One or two lM of GST or GST-TRF1 was incubated with human
mTOR kinase (Millipore), human bRAF WT or V600E kinases
(Millipore), or mouse ERK2 kinase (Millipore) in the presence of
5 lCi [c-32P]ATP. Note: For the analysis of BRAF and mTOR-depen-
dent TRF1 phosphorylation, we used catalytically active “human”
purified proteins consisting only in the catalytic C-terminal portion,
since the murine BRAF and mTOR were not available. Nevertheless,
albeit mouse and human mTOR proteins display 98.9% identity, the
identity between their C-terminal kinase domains is 100%; thus,
they exactly represent the same protein.
The following inhibitors were used: ERKi (SCH772984), MEKi
(Selumetinib), BRAFi (vemurafenib and dabrafenib), mTORi
(rapamycin and Ku0063794). The reactions were performed at 30°C
for 1 and stopped by addition of Lamely buffer (6×). Samples were
resolved in 4–12% SDS–PAGE followed by autoradiography.
Neurosphere formation assays
Patient-derived h676 spheres were dissociated into single cells and
seeded at a density of 100–200 cells/well in a 96-well plate. Neuro-
sphere number was assessed after 7 days. Nikon Eclipse Ti-U micro-
scope was used to take the pictures, and neurosphere diameter was
measured using NIS Elements BR software.
Generation of GST-TRF1 and eGFP-TRF1 mutant alleles
For site-directed mutagenesis, QuickChange XL II site-directed muta-
genesis (Agilent Technologies) was used. In brief, PCRs were
performed following the manufacturer’s protocol with either the
pDEST565-mTRF1 expression vector or the eGFP-TRF1 pWzl-Hygro
























PCR products were digested with Dpn I restriction enzyme to
digest the parental (non-mutated) DNA for 1 h at 37 °C and then
transformed into XL-10- Gold ultracompetent cells. Individual colo-
nies were grown and DNA extracted with QIAprep Spin Miniprep
Kit (27106, QIAGEN). Mutations were confirmed by sequencing
with a specific TRF1 primer 50-TTCCACTCCCTTTTCCAACACT-30.
Finally, 50 ng of each mutant DNA was used to transform BL21
(DE3). Protein production and phosphorylation of the respective
mutant GST-TRF1 protein were carried out following the same
protocols described above.
Identification of TRF1 phosphopeptides by LC/MS/MS analysis
1 lM or 2 lM of purified GST-TRF1 was incubated with 0.1 lM or
0.2 lM of either ERK2, mTOR, and BRAF in the proper kinase
buffer (50 mM Hepes pH 7.9, 100 lM ATP, 10 mM MgCl 2, 5 mM
DTT) in a total volume of 25 ll for 1 h at 30 °C. Protein samples
were diluted with 9 M urea in 50 mM ammonium bicarbonate
(ABC) and subsequently reduced and carbamidomethylated in
15 mM Tris(2-carboxyethyl)phosphine (TCEP) and 30 mM
chloroacetamide for 45 min at 25°C protected from light. After
diluting the urea to 2 M with 50 mM ABC, samples were digested
overnight with Lys-C (1:50 enzyme/protein w/w), diluted to 1 M
urea, and further digested with trypsin (1:50 enzyme/protein w/w)
for 6 h at 37°C. Resulting peptides were desalted by homemade
C18 Empore tips and analyzed by LC-MS/MS onto a LTQ-Orbitrap
Velos instrument. The raw files were processed using the
Proteome Discoverer 1.4.0.1 software. Fragmentation spectra were
searched against the mouse UniProtKB/TrEMBL database (43,539
entries), supplemented with a homemade database comprising the
contaminant proteins most commonly found in our assays, using
Sequest as the search engine. The precursor and fragment mass
tolerances were set to 20 p.p.m. and 0.5 Da, respectively, and up
to two tryptic missed cleavages were allowed. Carbamidomethyla-
tion of cysteine was considered as fixed modification, while oxida-
tion of methionine and phosphorylation of serine, threonine, and
tyrosine were chosen as variable modification for database search-
ing. The results were filtered to 1% false discovery rate (FDR)
using percolator.
Xenografts experiments
h676 and h543 patient-derived GSCs were dissociated using a 200-ll
pipette and resuspended in NeuroCult medium and Matrigel in a 1:1
ratio in a concentration of 1,000 cells/ll. Foxn1nu/nu mice were
subcutaneously injected with 100 ll of the cell preparation. The
mice were randomized and treated with the compounds which were
administrated as follows:
PI3Ki (ETP-47037): oral administration at a concentration of 75 mg/
kg or 50 mg/kg 5 days per weeks until the end-point, starting
1 week after cell injection. Vehicle: 10% NMP / 90% PEG.
18 of 21 EMBO Molecular Medicine 11: e10292 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Leire Bejarano et al
MEKi inhibitor (PD0325901): oral administration 5 days/week at a
concentration of 3 mg/kg, until the human end-point. Vehicle:
methylcellulose 0.5%: 0.2% Tween-80.
ERKi (VRT752271): oral administration 5 days/week at a concentra-
tion of 50 mg/kg, until the human end-point. Vehicle: 1% CMC.
RTKi (Dasatinib): oral administration 3 days/week at a concentra-
tion of 30 mg/kg, until the human end-point. Vehicle: 0.5% CMC
0.25% Tween-80.
Gemcitabine: intraperitoneal administration at a concentration of
125 mg/kg, once a week, until the human end-point. Vehicle:
saline.
Docetaxel: intraperitoneal administration at a concentration of
7.5 mg/kg, twice a week, until the human end-point. Vehicle:
saline.
HSP90i (Debio 0932): oral administration 3 days/week at a concen-
tration of 60 mg/kg, until the human end-point. Vehicle: 30%
Captisol.
Mice were weighed once a week for any sign in toxicity, and
tumors were measured every 2–4 days in a non-blinded manner.
Tumor area was determined by the following equation: A = p*
(a/2)*(b/2), where a and b are tumor length and width, respec-
tively. The tumor growth curves were plotted until the last mouse
died.
Immunofluorescence analyses in cells and tissue sections
For immunofluorescence analyses, we plated the cells in a proper
density in cell culture lCLEAR plates (Greiner) and we fixed them
in 4% formaldehyde in PBS. We incubated the cells with 0.25%
Triton in PBS followed by 5% BSA in PBS.
Tissue sections were fixed in 10% buffered formalin (Sigma) and
embedded in paraffin. After deparaffinization and citrate antigen
retrieval, we incubated the slides with 0.5% Triton in PBS and
blocked them with 1% BSA and 10% Australian FBS (Genycell) in
PBS.
The antibodies were applied overnight in antibody diluents with
background reducing agents (Invitrogen).
Primary antibodies: anti-Rap1 1:500 (BL735, Bethyl), anti-cH2AX
Ser139 1:500 (05-636, Millipore), anti-TRF1 1:500 (BED5, Bio-Rad).
Images were obtained using a confocal ultraspectral microscope
(Leica TCS-SP5). Quantifications were performed with Definiens
software.
Immunohistochemistry analyses in cells
For immunohistochemistry analyses, cells were fixed in 10%
buffered formalin (Sigma) and embedded in gelatine and paraffin.
Immunohistochemistry was performed on deparaffinated cell
sections treated with 10 mM sodium citrate (pH 6.5) cooked under
pressure for 2 min. Slides were blocked with peroxidase, washed
with TBS-Tween-20 0.5%, and blocked with fetal bovine serum
followed by another wash.
Primary antibodies included the following: cH2AX Ser139 (Milli-
pore), 1:150.
Slides were then incubated with secondary antibodies conjugated
with peroxidase from DAKO.
Olympus AX70 microscope was used to take the pictures. The
percentage of positive cells was counted by eye.
Quantitative telomere fluorescence in situ hybridization (Q-FISH)
on metaphase spreads
For metaphase preparation, cells were treated overnight with
0.1 lg/ml colcemid. Cells were incubated with hypotonic solution
(0.4% KCl, 0.4% sodium citrate) and fixed with cold methanol/
acetic acid (3:1). On the final steps, cells were spread on glass
slides. For quantitative telomere fluorescence in situ hybridization
(Q-FISH), slides were dehydrated with increasing concentrations of
EtOH (70%, 90%, 100%) and then incubated with the telomeric
probe for 3.5 min at 85°C followed by 2 h RT incubation in a wet
chamber. After the incubation, the slides were washed with 50%
formamide and 0.08% TBS-Tween.
Analysis of MTS signals was performed by superposing the FISH
telomere image and the DAPI image.
Western blots
Nuclear Cytosolic Fractionation Kit (BioVision) was used to
obtain protein extracts. Protein concentration was determined
using the Bio-Rad DC Protein Assay (Bio-Rad). Up to twenty
The paper explained
Problem
Eukaryotic chromosome ends, known as telomeres, are considered a
universal anti-cancer target as telomere maintenance is essential to
sustain cancer cell growth. Telomeres are protected by the so-called
shelterin complex, and thus, targeting of the shelterin complex may
be an effective anti-cancer strategy. We have previously demonstrated
that genetic and chemical inhibition of the shelterin protein TRF1
impairs tumor growth in mouse models of lung cancer and glioblas-
toma, including patient-derived xenograft models. However, resistance
to TRF1 chemical inhibitors eventually occurs, resulting in re-expres-
sion of the TRF1 protein and tumor growth. To find novel TRF1 inhibi-
tors, which could be used in combination therapies to effectively
block cancer growth, here we screened a collection of FDA-approved
drugs and drugs in clinical trials.
Results
We found that inhibition of several kinases of the Ras pathway,
including ERK and MEK, recapitulates the effects of Trf1 genetic dele-
tion, including induction of DNA damage at telomeres and inhibition
of cancer stemness. We further show that TRF1 is phosphorylated by
ERK in thirteen different residues. We identify three TRF1 phospho-
sites, whose ERK-dependent phosphorylation is required for proper
telomere protection. Finally, we explore novel drug combinations
based on TRF1 inhibition, with the aim of effectively blocking poten-
tial resistance to individual drugs in patient-derived glioblastoma
xenograft models.
Impact
Glioblastoma is the most aggressive brain tumor, and despite treat-
ment with chemotherapy, radiation, surgery-based combined treat-
ments, it very frequently relapses. Thus, new therapeutic approaches
are needed to effectively block glioblastoma growth. We have shown
that TRF1 inhibition is a potent way to impair glioblastoma growth.
Here, we show that multiple cancer pathways, including the Ras
pathway, are potential therapeutic targets to inhibit TRF1 in cancer.
Our findings further show the potential of combination therapies
based on TRF1 inhibition as a promising therapeutic strategy to over-
come drug resistance and effectively block glioblastoma growth.
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micrograms of nuclear protein extracts was separated in SDS–
polyacrylamide gels by electrophoresis. After protein transfer
onto nitrocellulose membrane, the membranes were incubated
with the indicated antibodies. Antibody binding was detected
after incubation with a secondary antibody coupled to horse-
radish peroxidase using chemiluminescence with ECL detection
KIT (GE Healthcare).
Primary antibodies: anti-TRF1 1:1,000 (BED5, Bio-Rad), anti-
TRF1 1:500 (homemade), anti-SMC-1 1:2,000 (Bethyl), anti-AKT1
1:500 (Millipore), anti-p-AKT 1:500 (Ser473, Cell Signaling Cell
Signaling Technology), anti-S6 1:500 (Cell Signaling Cell Signaling
Technology), anti-p-S6 1:500 (Ser240/244, Cell Signaling Technol-
ogy), anti-TIN2 1:1,000 (Abcam), anti-RAP1 1:1,000 (Bethyl).
For the quantification, protein-band intensities have been quanti-
fied by densitometric analysis with ImageJ software. The Trf1 total
levels have been normalized versus SMC1 and the mean of the
Trf1/SMC1 ratio deriving from at least 3 different replicates has
been used to generate the chart.
Combinatorial studies
For the combination studies, the concentration that produces 50%
of the inhibition (EC50) in the growth of glioma stem cells is calcu-
lated. Using this concentration as a reference point, a combinatorial
matrix is designed using different concentrations of the compounds
(e.g., 2x EC50, EC50, and ½ EC50) to study all the possible combi-
nations. Combination index is calculated to establish if the combina-
tion is synergistic, additive, or antagonistic based on the Chou–
Talay method (Chou, 2010).
Quantification and statistical analysis
Immunofluorescence quantifications were performed with Definiens
software, and immunohistochemistry quantifications were
performed by direct cell counting. Western blot protein-band inten-
sities were measured with ImageJ software and normalized against
the loading control.
Unpaired Student’s t-test (two-tailed) or chi-square was used to
determine statistical significance. P-values of less than 0.05 were
considered significant. *P < 0.05, **P < 0.01, ***P < 0.001. Statisti-
cal analysis was performed using Microsoft Excel 2011. All in vitro
experiments were repeated at least twice (biological replicates) with
two or more technical replicates. The exact P-values are listed in
Appendix Table S2.
Expanded View for this article is available online.
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